Extended Follow-Up May Elucidate How ctDNA Impacts RMC-6236 PDAC Outcomes
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Related Articles
CHMP Recommends Liso-cel in Pretreated R/R Follicular Lymphoma for Approval
The TRANSCEND FL trial showed that liso-cel elicited an ORR of 97.1% and a complete response rate of 94.2% in patients with follicular lymphoma.
FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer
The FDA accepted a BLA seeking the approval of the pertuzumab biosimilar HLX11 for HER2-positive breast cancer.
Accommodations and Travel
Note Regarding Fraudulent Housing Websites CMR (Convention Management Resources) is the official hotel management company for the AACR Annual Meeting. The AACR is aware that…
‘Clinically meaningful’ outcomes in cancer care extend beyond survival
A qualitative study yielded important insights about how patients, caregivers and clinicians define what truly is clinically meaningful.People living with metastatic breast cancer were not…
Home | AML Hub
Online resource for healthcare professionals, providing information, news & support relating to AML
2025 ASTRO Annual Refresher Course – American Society for Radiation Oncology (ASTRO)
Learn more about the 2025 ASTRO Annual Refresher Course.
Blocking IL-4 May Improve Immunotherapy Response in Ovarian … : Oncology Times
An abstract is unavailable.
Prognostic and biological divergence of upper gastrointestinal adenocarcinomas.
350Background: Esophageal (EAC), gastroesophageal junction (GEJ) or gastric (GAC) adenocarcinoma share similar etiologies and treatment approaches. However, it is not clear if they possess similar…
🚨 The OncoAlert Colloquium Feb 2025
A 100% virtual, week-long meeting highlighting the most important developments in oncology each year, delivered by some of the world’s leading oncologists in a multidisciplinary…
Encorafenib/Cetuximab Plus Chemo Improves Survival in BRAF V600E+ mCRC
Encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS vs chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.